Clinical Trials Directory

Trials / Completed

CompletedNCT06737458

Serratus Anterior Plane Block Versus Erector Spinae Plane Block With Dexmedetomidine Added to Bupivacaine for Ultrasound-Guided Pain Management After Mastectomy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Kafrelsheikh University · Academic / Other
Sex
Female
Age
20 Years
Healthy volunteers
Not accepted

Summary

This study aimed to compare the serratus plane block versus the erector spinae plane block with dexmedetomidine added to bupivacaine for acute pain management after breast surgeries.

Detailed description

Approximately 40-60% of breast surgery patients endure severe acute postoperative pain, with over 10% of patients experiencing severe pain for six to twelve months (post-mastectomy pain syndrome). Dexmedetomidine has analgesic properties, which could be related to the stimulation of α2 adrenoceptors, inhibition of nerve conduction through C and Aδ fibers, and the local release of encephalin. Serratus plane block (SPB) is an effective approach for breast surgery analgesia due to its simplicity of delivery, minimal risk of adverse effects, and ability to provide significant pain relief. The erector spinae plane block (ESPB) is one of the emerging regional techniques for managing postoperative pain. ESPB can be given unilaterally during modified radical mastectomy.

Conditions

Interventions

TypeNameDescription
DRUGBupivacaine + DexmedetomidinePatients received serratus anterior plane block on the operated side with bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.
DRUGBupivacaine + DexmedetomidinePatients received erector spinae plane block at T5 on the operated side and will receive bupivacaine 0.25% plus 0.5 µg/kg dexmedetomidine in 30 ml.

Timeline

Start date
2023-07-01
Primary completion
2024-07-01
Completion
2024-07-01
First posted
2024-12-17
Last updated
2024-12-17

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06737458. Inclusion in this directory is not an endorsement.